New treatment news for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

A recent study shows that Alecensa® as an initial (first-line) treatment significantly reduced the risk of disease worsening or death compared to crizotinib in people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Read the article: http://finance.yahoo.com/news/phase-iii-study-shows-genentech-050000040.html